1. Linezolid in enterococcal urinary tract infection: a multicentre study.
- Author
-
Malinowski, Léa, Zayet, Souheil, Chiaruzzi, Myriam, Lefevre, Benjamin, Baronnet, Guillaume, Blot, Mathieu, Klopfenstein, Timothée, Piroth, Lionel, Chirouze, Catherine, Sotto, Albert, and Bouiller, Kevin
- Subjects
- *
URINARY tract infections , *ENTEROCOCCUS faecalis , *TERMINATION of treatment , *LINEZOLID , *ENTEROCOCCUS faecium - Abstract
Purpose: Few data have been published on the efficacy of linezolid in enterococcal urinary tract infection (e-UTI). The aims of this study were to describe the characteristics of patients with enterococci UTI treated with linezolid, and to evaluate the efficacy and the tolerance of linezolid treatment. Methods: An observational multicentre retrospective study was conducted in 5 hospitals in France. Patients were included if they met the following criteria: ≥18 years, clinical and microbiological criteria for enterococcal UTI and linezolid treatment > 48 h. Primary outcome was clinical failure. Results: Eighty-one patients were included between January 2015 and December 2021. The median age was 73.0 [64; 83] years and 47 (58%) were men. The median Charlson comorbidity index was 3.00 [2; 6]. E. faecium was reported in 65 (80%) cases and E. faecalis in 26 cases (32%). Polymicrobial infections occurred in 41 (51%) cases. No enterococci was resistant to vancomycin. Before linezolid prescription an empiric antimicrobial treatment was started in 48 (59%) cases and was effective against enterococci in 19/48 (39.5%) patients for a median of 3.5 days [2.0; 4.0]. The median duration of linezolid antibiotic treatment was 13 days [10; 14]. Three adverse events were reported, none were serious but one led to discontinuation of treatment. Treatment failure was reported in 2 cases (2.5%). Conclusion: This study provides evidence for efficacy and safety of linezolid in enterococcal UTI. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF